IL4R and Alzheimer disease: In our study, anti-IL4Rα and ruxolitinib were generally successful in restoring skin barrier and inflammatory responses in the AD-RHE model (Figure 1, Figure 2, Figure 3, Figure 4, Figure 5 and Figure 6, Table 1).